Travere says Phase 2 SPARTAN final analysis shows 75% complete proteinuria remission with FILSPARI in IgA nephropathy

• Travere Therapeutics flagged nine new data presentations on FILSPARI for IgA nephropathy, focal segmental glomerulosclerosis at ASN Kidney Week 2026.
• Results will be presented October 21-25 in Denver, including final Phase 2 SPARTAN findings in newly diagnosed IgA nephropathy.
• SPARTAN showed many patients reached complete proteinuria remission, with kidney function remaining broadly stable over two years.
• A Phase 3 DUPLEX post hoc analysis in FSGS without nephrotic syndrome favored FILSPARI over irbesartan on proteinuria remission measures.
• The same analysis indicated slower kidney function loss, fewer kidney failure events, with a comparable overall safety profile versus irbesartan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001650352) on October 02, 2026, and is solely responsible for the information contained therein.